All In Biotech

NDA 204141 · Sun Pharma Canada

Topicort

Desoximetasone · Topical · Corticosteroid

Last checked: Nov 20, 2026Latest source record: Oct 7, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2013

Apr 11, 2013

Approved uses

2

Original approval plus efficacy supplements

Registered trials

10

4 Phase 3, 0 recruiting

FAERS reports

19,273

18,360 serious, 5,296 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jul 8, 2025.

Desoximetasone Topical Spray is a corticosteroid indicated for the treatment of plaque psoriasis in patients 18 years of age or older. Desoximetasone Topical Spray is a corticosteroid indicated for the treatment of plaque psoriasis in patients 18 years of age or older ( 1 ).

Mechanism: Corticosteroids play a role in cellular signaling, immune function, inflammation and protein regulation; however, the precise mechanism of action in psoriasis is unknown.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • TOPICORT · DESOXIMETASONE 0.25% · SPRAY, TOPICAL · Prescription · TE AT

Clinical trials

Interventional ClinicalTrials.gov studies with "Desoximetasone" as an intervention, any sponsor and status, largest first.

All 10 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective10,104
  • pain9,142
  • fatigue9,090
  • rheumatoid arthritis8,445
  • alopecia8,417
  • systemic lupus erythematosus8,376
  • pemphigus8,111
  • abdominal discomfort8,037
  • glossodynia7,884
  • swelling7,357
  • hand deformity7,164
  • rash7,093

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20044
20053
200610
20074
200812
200916
201019
201119
201245
201347
201464
2015142
2016269
2017413
2018520
20191,058
20202,045
20213,122
20222,964
20231,681
20243,180
20252,609
20261,027

Recalls

1 FDA enforcement reports for this application.

  • Aug 5, 2015 · Class III · Terminated

    Failed Impurities/Degradation Specifications: Out of specification results for impurities testing was obtained at the 6 and 9 month time points.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 38 on PubMed

Sponsor: Sun Pharma Canada

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.